Applied sciences for Viral Vector Manufacturing

Manufacturing of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparability of Platform Applied sciences for Viral Vector Manufacturing

Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination in opposition to numerous difficult pathogens or the remedy of some kinds of cancers. As a result of this vector is unable to duplicate in human recipients, a excessive quantity of virions per dose is required for vaccination and gene remedy. Upstream course of intensification combining perfusion applied sciences, the avian suspension cell line AGE1.CR.pIX and the virus pressure MVA-CR19 is an choice to acquire very excessive MVA yields.

Right here we in contrast totally different choices for cell retention in perfusion mode utilizing typical stirred-tank bioreactors together with an alternating tangential stream filtration system, an acoustic settler and an inclined settler. The final two choices allowed steady MVA virus harvesting. Moreover, we studied hollow-fiber based mostly bioreactors and an orbital-shaken bioreactor in perfusion mode, each accessible for single-use. Productiveness for the virus pressure MVA-CR19 was in comparison with outcomes from batch and steady manufacturing reported in literature.

Our outcomes display that MVA virus is extremely steady at 37°C in cell tradition in order that cell retention gadgets are solely required to maximise cell focus however not for steady harvesting. Utilizing a stirred-tank bioreactor, a perfusion technique throughout the entire run with working quantity enlargement after virus an infection resulted within the highest yields.

General, infectious MVA virus titers of two.1-16.5 × 10⁹ virions/mL have been achieved in these intensified processes. Taken collectively, the examine exhibits a novel perspective on high-yield MVA virus manufacturing in typical bioreactor methods linked to numerous cell retention gadgets and addresses choices for course of intensification together with absolutely single-use perfusion platforms. This text is protected by copyright. All rights reserved.

Human IGF-BP4
MBS692040-002mg	MyBiosource	0.02mg	EUR 450

Human IGF-BP4
MBS692040-5x002mg	MyBiosource	5x0.02mg	EUR 1725

IGF BP4 protein
30R-AI123	Fitzgerald	20 ug	EUR 312
Description: Purified recombinant Human IGF BP4 protein

IGF BP4 protein
MBS539608-002mg	MyBiosource	0.02mg	EUR 465

IGF BP4 protein
MBS539608-5x002mg	MyBiosource	5x0.02mg	EUR 1945

Anti-Human IGF-BP4 Antibody
101-M460	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF-BP4, human recombinant
7166-10	Biovision	each	EUR 301.2

IGF-BP4, human recombinant
7166-50	Biovision	each	EUR 1123.2

Human IGF-BP4 Recombinant Protein
100-200	ReliaTech	20 µg	EUR 196.35
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Human IGF-BP4 Recombinant Protein
100-200S	ReliaTech	5 µg	EUR 92.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF-BP4 Protein
PROTP22692-1	BosterBio	20ug	EUR 380.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. *Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Human IGF-BP4 Recombinant Protein Lyophilized
IHUIGFBP4RLY5UG	Innovative research	each	EUR 341
Description: Human IGF-BP4 Recombinant Protein Lyophilized

Human IGF-BP4 Recombinant Protein Lyophilized
MBS8432291-INQUIRE	MyBiosource	INQUIRE	Ask for price

IGF-BP4 Recombinant Protein
40-318-0005mg	ProSci	0.005 mg	EUR 311.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

IGF-BP4 Recombinant Protein
40-318-002mg	ProSci	0.02 mg	EUR 437.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF BP3
HEGFP-0903	Cyagen	5ug	Ask for price

Recombinant Human IGF BP5
HEGFP-0905	Cyagen	5ug	Ask for price

Recombinant Human IGF BP7
HEGFP-0907	Cyagen	5ug	Ask for price

human anti-human IGF-1 mAb(6E)
E4A09K04-6E	EnoGene	50ug	EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IGF-1 mAb(8D)
E4A09K04-8D	EnoGene	50ug	EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18
IRBAHURIPK1IGF18C100UL	Innovative research	each	EUR 496
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

Human IGF-BP7
MBS691503-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP7
MBS691503-0025mg	MyBiosource	0.025mg	EUR 450

Human IGF-BP7
MBS691503-5x0025mg	MyBiosource	5x0.025mg	EUR 1725

Human IGF-BP6
MBS691832-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP6
MBS691832-002mg	MyBiosource	0.02mg	EUR 450

Human IGF-BP6
MBS691832-5x002mg	MyBiosource	5x0.02mg	EUR 1725

Human IGF-BP3
MBS692057-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP3
MBS692057-0025mg	MyBiosource	0.025mg	EUR 450

Human IGF-BP3
MBS692057-5x0025mg	MyBiosource	5x0.025mg	EUR 1725

Human IGF-BP2
MBS692085-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP2
MBS692085-002mg	MyBiosource	0.02mg	EUR 450

Human IGF-BP2
MBS692085-5x002mg	MyBiosource	5x0.02mg	EUR 1725

Human IGF-BP1
MBS692092-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP1
MBS692092-0025mg	MyBiosource	0.025mg	EUR 450

Human IGF-BP1
MBS692092-5x0025mg	MyBiosource	5x0.025mg	EUR 1725

Human IGF-BP5
MBS692152-0005mg	MyBiosource	0.005mg	EUR 300

Human IGF-BP5
MBS692152-0025mg	MyBiosource	0.025mg	EUR 450

Human IGF-BP5
MBS692152-5x0025mg	MyBiosource	5x0.025mg	EUR 1725

Human IGF-1
MBS691641-01mg	MyBiosource	0.1mg	EUR 300

Human IGF-1
MBS691641-05mg	MyBiosource	0.5mg	EUR 450

Human IGF-1
MBS691641-5x05mg	MyBiosource	5x0.5mg	EUR 1725

Human IGF-2
MBS691655-001mg	MyBiosource	0.01mg	EUR 300

Human IGF-2
MBS691655-005mg	MyBiosource	0.05mg	EUR 450

Human IGF-2
MBS691655-5x005mg	MyBiosource	5x0.05mg	EUR 1725

IGF-BP3, Human
HY-P7020	MedChemExpress	10ug	EUR 280.8

IGF-BP5, Human
HY-P7021	MedChemExpress	50ug	EUR 721.2

IGF-BP3, human
RC216-12B3	Bio Basic	5ug	EUR 125.26

Anti-Human IGF-BP1 Antibody
101-M457	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP2 Antibody
101-M458	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody
101-M459	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody
101-M461	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP6 Antibody
101-M462	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody
101-M463	ReliaTech	100 µg	EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody
102-P144	ReliaTech	100 µg	EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody
102-P232	ReliaTech	100 µg	EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody
102-P233	ReliaTech	100 µg	EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF BP3 antibody
70R-IR022	Fitzgerald	50 ug	EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody

IGF BP5 antibody
70R-IR023	Fitzgerald	50 ug	EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody

IGF BP7 antibody
70R-IR024	Fitzgerald	50 ug	EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody

IGF BP7 antibody
MBS535700-005mg	MyBiosource	0.05mg	EUR 465

IGF BP7 antibody
MBS535700-5x005mg	MyBiosource	5x0.05mg	EUR 1945

IGF BP3 antibody
MBS535722-005mg	MyBiosource	0.05mg	EUR 465

IGF BP3 antibody
MBS535722-5x005mg	MyBiosource	5x0.05mg	EUR 1945

IGF BP5 antibody
MBS535907-005mg	MyBiosource	0.05mg	EUR 465

IGF BP5 antibody
MBS535907-5x005mg	MyBiosource	5x0.05mg	EUR 1945

IGF-1, Human
HY-P7018	MedChemExpress	10ug	EUR 129.6

IGF-2, Human
HY-P7019	MedChemExpress	100ug	EUR 432

IGF-1, human
RC216-12	Bio Basic	1mg	EUR 451.5

IGF-1 (Human)
MBS352114-1Bottle	MyBiosource	1Bottle	EUR 350

IGF-1 (Human)
MBS352114-5x1Bottle	MyBiosource	5x1Bottle	EUR 1490

IGF-1 (Human)
MBS352116-01mL	MyBiosource	0.1mL	EUR 450

IGF-1 (Human)
MBS352116-5x01mL	MyBiosource	5x0.1mL	EUR 1950

IGF-2 (Human)
MBS352118-1Bottle	MyBiosource	1Bottle	EUR 350

IGF-2 (Human)
MBS352118-5x1Bottle	MyBiosource	5x1Bottle	EUR 1490

Recombinant Human LR3 IGF-I/IGF-1
PH2031-.01	ApexBio	10ug	EUR 208
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human LR3 IGF-I/IGF-1
PH2031-.1	ApexBio	10X10ug	EUR 496
Description: Peptides & Proteins|Recombinant Proteins

Anti-Human IGF-1 Antibody
101-M454	ReliaTech	100 µg	EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody
101-M456	ReliaTech	100 µg	EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-1 Antibody
102-P28	ReliaTech	100 µg	EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody
102-P29	ReliaTech	100 µg	EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)
MBS635918-005mg	MyBiosource	0.05mg	EUR 495

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)
MBS635918-5x005mg	MyBiosource	5x0.05mg	EUR 2075

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)
MBS650945-001mg	MyBiosource	0.01mg	EUR 390

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)
MBS650945-005mg	MyBiosource	0.05mg	EUR 540

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)
MBS650945-5x005mg	MyBiosource	5x0.05mg	EUR 2275

Antibody for Human IGF-1
SPC-699D-A565	Stressmarq	0.1mg	EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.

Antibody for Human IGF-1
SPC-699D-A633	Stressmarq	0.1mg	EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.

Antibody for Human IGF-1
SPC-699D-A655	Stressmarq	0.1mg	EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.

Antibody for Human IGF-1
SPC-699D-A680	Stressmarq	0.1mg	EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.

Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Focused Gene Supply to Melanoma Cells Metastasized to the Lung

Background/goal: Sufferers with metastasized melanoma have restricted remedy choices and poor analysis. Subsequently, the event of therapies requires a brand new therapeutic strategy, of which gene remedy utilizing rAAV vectors might be proposed. The goal of the examine was to look at the effectivity of the rAAV vector to transduce mouse melanoma cells each in vitro and in vivo.

Supplies and strategies: Totally different rAAV serotypes encoding GFP underneath the management of each hen beta-actin and cytomegalovirus promoters have been used within the experiments. Intranasal, intraperitoneal, intravenous and intratumoral pathways of administration of rAAV vectors have been examined utilizing quantitative-PCR and immunohistochemical staining.

Outcomes: The very best transduction effectivity in metastatic cells in vivo was noticed 7 days after intranasal administration of a 10¹⁰ gc/0.03 ml dose of rAAV/DJ-CAG.

Conclusion: Melanoma gene remedy based mostly on rAAV vectors is a attainable remedy possibility.

Vector Competence of Aedes aegypti, Aedes albopictus and Culex quinquefasciatus from Brazil and New Caledonia for Three Zika Virus Lineages

Zika virus (ZIKV) has prompted extreme epidemics in South America starting in 2015, following its unfold via the Pacific. We comparatively assessed the vector competence of ten populations of Aedes aegypti and Ae. albopictus from Brazil and two of Ae. aegypti and one in all Culex quinquefasciatus from New Caledonia to transmit three ZIKV isolates belonging to African, Asian and American lineages.

Just lately colonized mosquitoes from eight distinct websites from each international locations have been orally challenged with the identical viral load (10⁷ TCID₅₀/mL) and examined after 7, 14 and 21 days. Cx. quinquefasciatus was refractory to an infection with all virus strains. In distinction, though competence assorted with geographical origin, Brazilian and New Caledonian Ae. aegypti may transmit the three ZIKV lineages, with a robust benefit for the African lineage (the one one reaching saliva one-week after problem).

Brazilian Ae. albopictus populations have been much less competent than Ae. aegypti populations. Ae. albopictus usually exhibited nearly no transmission for Asian and American lineages, however was environment friendly in transmitting the African ZIKV. Viral surveillance and mosquito management measures should be strengthened to keep away from the unfold of latest ZIKV lineages and decrease the transmission of viruses at the moment circulating.

Human anti-Human IL-8 mAb
MBS8576808-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 565

human anti-human IL-8 mAb (A5)
E4A09D07-A5A	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

human anti-human IL-8 mAb (6G)
E4A09D07-B5G	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

human anti-human IL-8 mAb (AB)
E4A09D07-C8A	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

human anti-human IL-8 mAb(N2)
E4A09D07-N2	EnoGene	50ug	EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IL-8 mAb(N8)
E4A09D07-N8	EnoGene	50ug	EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IL-8 mAb(1F)
E4A09D07-1F	EnoGene	100ug	EUR 595

Anti-Human IL-8
GWB-BIG258	GenWay Biotech	500ug	Ask for price

human anti-human IL-8 mAb (1H) Humanized Antibody
MBS8574794-01mg	MyBiosource	0.1mg	EUR 505

human anti-human IL-8 mAb (1H) Humanized Antibody
MBS8574794-5x01mg	MyBiosource	5x0.1mg	EUR 2015

human anti-human IL-8 mAb (2H) Humanized Antibody
MBS8574795-01mg	MyBiosource	0.1mg	EUR 505

human anti-human IL-8 mAb (2H) Humanized Antibody
MBS8574795-5x01mg	MyBiosource	5x0.1mg	EUR 2015

Human Interleukin-8 (IL-8) Antibody
13102-05011	AssayPro	150 ug	EUR 175

Human IL-8
90258-A	BPS Bioscience	5 µg	EUR 130
Description: Recombinant human Interleukin-8 is a disulfide-linked monomer protein consisting of 78 amino acid residues, migrates as an approximately 9 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Interleukin-8 mature chain was expressed in E. coli.

Human IL-8
90258-B	BPS Bioscience	25 µg	EUR 205
Description: Recombinant human Interleukin-8 is a disulfide-linked monomer protein consisting of 78 amino acid residues, migrates as an approximately 9 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Interleukin-8 mature chain was expressed in E. coli.

human IL-8
M851530020	Tecan Benelux	1 unit	EUR 804.84

human-anti-human-IL-8-mAb(1H)
E409C16-hA100	EnoGene	Inflammation-Storm-Antibodies	EUR 276.5
Description: Inflammation Storm Antibodies

human-anti-human-IL-8-mAb(2H)
E409C16-hB100	EnoGene	Inflammation-Storm-Antibodies	EUR 276.5
Description: Inflammation Storm Antibodies

Anti-Human IL-8 Antibody
101-M08	ReliaTech	500 µg	EUR 246.75
Description: Il-8 or CXCL8 was originally discovered and purified as a neutrophil chemotactic and activating factor. It was also referred to as neutrophil chemotactic factor (NCF), neutrophil activating protein (NAP), monocytederived neutrophil chemotactic factor (MDNCF), T lymphocyte chemotactic factor (TCF), granulocyte chemotactic protein (GCP) and leukocyte adhesion inhibitor (LAI). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes, and various tumor cell lines, can produce CXCL8 in response to a wide variety of proinflammatory stimuli such as exposure to IL-1, TNF, LPS, and viruses. CXCL8 is a member of the alpha (CXC) subfamily of chemokines, which also includes platelet factor-4, GRO, and IP10.

Anti-Human IL-8 Antibody
102-P38	ReliaTech	100 µg	EUR 245.7
Description: Il-8 or CXCL8 was originally discovered and purified as a neutrophil chemotactic and activating factor. It was also referred to as neutrophil chemotactic factor (NCF), neutrophil activating protein (NAP), monocytederived neutrophil chemotactic factor (MDNCF), T lymphocyte chemotactic factor (TCF), granulocyte chemotactic protein (GCP) and leukocyte adhesion inhibitor (LAI). Many cell types, including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, keratinocytes, hepatocytes, chondrocytes, and various tumor cell lines, can produce CXCL8 in response to a wide variety of proinflammatory stimuli such as exposure to IL-1, TNF, LPS, and viruses. CXCL8 is a member of the alpha (CXC) subfamily of chemokines, which also includes platelet factor-4, GRO, and IP10.

Anti-Human IL-8 Antibody
GWB-817E77	GenWay Biotech	1 mL	Ask for price

mAb anti-Human IL-8
MBS592019-01mg	MyBiosource	0.1mg	EUR 365

mAb anti-Human IL-8
MBS592019-05mg	MyBiosource	0.5mg	EUR 530

mAb anti-Human IL-8
MBS592019-5x05mg	MyBiosource	5x0.5mg	EUR 2140

mAb anti-Human IL-8
MBS592095-01mg	MyBiosource	0.1mg	EUR 365

mAb anti-Human IL-8
MBS592095-05mg	MyBiosource	0.5mg	EUR 530

mAb anti-Human IL-8
MBS592095-5x05mg	MyBiosource	5x0.5mg	EUR 2140

mAb anti-Human IL-8
MBS592159-01mg	MyBiosource	0.1mg	EUR 365

mAb anti-Human IL-8
MBS592159-05mg	MyBiosource	0.5mg	EUR 545

mAb anti-Human IL-8
MBS592159-5x05mg	MyBiosource	5x0.5mg	EUR 2205

mAb anti-Human IL-8
MBS592219-01mg	MyBiosource	0.1mg	EUR 365

mAb anti-Human IL-8
MBS592219-05mg	MyBiosource	0.5mg	EUR 545

mAb anti-Human IL-8
MBS592219-5x05mg	MyBiosource	5x0.5mg	EUR 2205

mAb anti-Human IL-8
MBS592256-01mg	MyBiosource	0.1mg	EUR 365

mAb anti-Human IL-8
MBS592256-05mg	MyBiosource	0.5mg	EUR 530

mAb anti-Human IL-8
MBS592256-5x05mg	MyBiosource	5x0.5mg	EUR 2140

Mouse Anti-Human IL-8
MBS690051-05mg	MyBiosource	0.5mg	EUR 525

Mouse Anti-Human IL-8
MBS690051-5x05mg	MyBiosource	5x0.5mg	EUR 2080

Anti-Human IL-8 (CXCL8)
MBS550689-01mg	MyBiosource	0.1mg	EUR 260

Anti-Human IL-8 (CXCL8)
MBS550689-02mg	MyBiosource	0.2mg	EUR 335

Anti-CXCL8 / IL-8 Reference Antibody (Genentech anti-IL-8)
E24CHA784	EnoGene	100 μg	EUR 225
Description: Available in various conjugation types.

Human IL-8 (77aa)
MBS691916-0005mg	MyBiosource	0.005mg	EUR 300

Human IL-8 (77aa)
MBS691916-0025mg	MyBiosource	0.025mg	EUR 450

Human IL-8 (77aa)
MBS691916-5x0025mg	MyBiosource	5x0.025mg	EUR 1725

IL-8 (72aa), Human
MBS8575167-0005mg	MyBiosource	0.005mg	EUR 245

IL-8 (72aa), Human
MBS8575167-5x0005mg	MyBiosource	5x0.005mg	EUR 940

IL-8/CXCL8, Human
HY-P7224	MedChemExpress	50ug	EUR 596.4

Human CXCL8 (IL-8)
MBS444011-0005mg	MyBiosource	0.005mg	EUR 150

Human CXCL8 (IL-8)
MBS444011-002mg	MyBiosource	0.02mg	EUR 210

Human CXCL8 (IL-8)
MBS444011-005mg	MyBiosource	0.05mg	EUR 325

Human CXCL8 (IL-8)
MBS444011-01mg	MyBiosource	0.1mg	EUR 480

Human CXCL8 (IL-8)
MBS444011-1mg	MyBiosource	1mg	EUR 1910

Human CXCL8 (IL-8)
MBS444019-0002mg	MyBiosource	0.002mg	EUR 195

Human CXCL8 (IL-8)
MBS444019-001mg	MyBiosource	0.01mg	EUR 530

Human CXCL8 (IL-8)
MBS444019-005mg	MyBiosource	0.05mg	EUR 1760

Human CXCL8 (IL-8)
MBS444019-01mg	MyBiosource	0.1mg	EUR 2890

Human IL-8 Protein
abx060803-25ug	Abbexa	25 ug	EUR 644.4

Human IL-8 Protein
abx060804-25ug	Abbexa	25 ug	EUR 644.4

Human IL-8 protein
PRP1022-100ug	Abbkine	100 μg	EUR 449
Description: Human IL-8 protein, expressed in E. coli

Human IL-8 protein
PRP1022-10ug	Abbkine	10 μg	EUR 59
Description: Human IL-8 protein, expressed in E. coli

Human IL-8 protein
PRP1022-1mg	Abbkine	1 mg	EUR 2609
Description: Human IL-8 protein, expressed in E. coli

Human IL-8 protein
PRP1022-50ug	Abbkine	50 μg	EUR 249
Description: Human IL-8 protein, expressed in E. coli

Human IL-8 Protein
E2RB20061PT	EnoGene	100ul	EUR 485
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Human IL-8 protein
MBS9719016-001mg	MyBiosource	0.01mg	EUR 115

Human IL-8 protein
MBS9719016-005mg	MyBiosource	0.05mg	EUR 225

Human IL-8 protein
MBS9719016-01mg	MyBiosource	0.1mg	EUR 345

Human IL-8 protein
MBS9719016-1mg	MyBiosource	1mg	EUR 1745

Human IL-8 protein
MBS9719016-5x1mg	MyBiosource	5x1mg	EUR 7815

Recombinant Human IL-8 (72a.a.)(rHu IL-8/CXCL8)
701081	SAB	25ul	EUR 235
Description: Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human CXCR2 transfected mouse BaF3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.

Recombinant Human IL-8 (77a.a.)(rHu IL-8/CXCL8)
701082	SAB	25ul	EUR 235
Description: Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human CXCR2 transfected mouse BaF3 cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 × 105 IU/mg.

Recombinant Human IL-8 (72a.a.) (rHu IL-8/CXCL8)
MBS9419956-0025mL	MyBiosource	0.025mL	EUR 280

Recombinant Human IL-8 (72a.a.) (rHu IL-8/CXCL8)
MBS9419956-5x0025mL	MyBiosource	5x0.025mL	EUR 1120

Recombinant Human IL-8
6487	Immunochemistry	5 µg	EUR 194

Recombinant Human IL-8
SJB05-01	Amyotop	25µg/vial	EUR 342

Recombinant Human IL-8
MBS7608414-005mg	MyBiosource	0.05mg	EUR 345

Recombinant Human IL-8
MBS7608414-02mg	MyBiosource	0.2mg	EUR 635

Recombinant Human IL-8
MBS7608414-1mg	MyBiosource	1mg	EUR 1800

Recombinant Human IL-8
MBS7608414-5x1mg	MyBiosource	5x1mg	EUR 6955

Recombinant Human IL-8
MBS258218-0005mg	MyBiosource	0.005mg	EUR 305

Recombinant Human IL-8
MBS258218-5x0005mg	MyBiosource	5x0.005mg	EUR 1210

Interleukin-8 (IL-8) (72a.a) Human
GWB-3997EC	GenWay Biotech	0.025 mg	Ask for price

Interleukin 8, Recombinant, Human (IL-8)
MBS650704-01mg	MyBiosource	0.1mg	EUR 475

Interleukin 8, Recombinant, Human (IL-8)
MBS650704-05mg	MyBiosource	0.5mg	EUR 775

Interleukin 8, Recombinant, Human (IL-8)
MBS650704-5x05mg	MyBiosource	5x0.5mg	EUR 3330

Interleukin 8, Recombinant, Human (IL-8)
MBS650074-0025mg	MyBiosource	0.025mg	EUR 665

Interleukin 8, Recombinant, Human (IL-8)
MBS650074-5x0025mg	MyBiosource	5x0.025mg	EUR 2845

Anti-Human IL-8 (257) Antibody
MBS4158332-01mg	MyBiosource	0.1mg	EUR 685

Anti-Human IL-8 (257) Antibody
MBS4158332-5x01mg	MyBiosource	5x0.1mg	EUR 2820

Anti-Human IL-8 (807) Antibody
MBS4158333-01mg	MyBiosource	0.1mg	EUR 685

Anti-Human IL-8 (807) Antibody
MBS4158333-5x01mg	MyBiosource	5x0.1mg	EUR 2820

Anti-IL-8 Antibody
A00423	BosterBio	1 mL	EUR 1444.8
Description: Rabbit Polyclonal IL-8 Antibody. Validated in IP, WB and tested in Human.

Anti-IL-8 Antibody
A2062-100	Biovision	100 µg	EUR 472.8

Anti-IL-8 Antibody
Y123169	ABM	100 µl	EUR 320

Anti-IL-8 Antibody
ER1706-67	HUABIO	100ul	EUR 189
Description: Interleukin 8 (IL-8 or chemokine (C-X-C motif) ligand 8, CXCL8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells. IL-8, also known as neutrophil chemotactic factor, has two primary functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection. IL-8 also stimulates phagocytosis once they have arrived. IL-8 is also known to be a potent promoter of angiogenesis. In target cells, IL-8 induces a series of physiological responses required for migration and phagocytosis, such as increases in intracellular Ca2+, exocytosis (e.g. histamine release), and the respiratory burst. IL-8 can be secreted by any cells with toll-like receptors that are involved in the innate immune response and has been demonstrated to be a signatory chemokine of CR2+ naive T cells, also known as recent thymic emigrants. Usually, it is the macrophages that see an antigen first, and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been reported to be potent inducers of the chemokine receptors CXCR1 and CXCR2. The homodimer is more potent, but methylation of Leu25 can block the activity of homodimers.

Anti-IL-8 Antibody
ER1901-61	HUABIO	100ul	EUR 189
Description: IL-8, also known as neutrophil chemotactic factor, has two primary functions. It induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection. IL-8 also stimulates phagocytosis once they have arrived. IL-8 is also known to be a potent promoter of angiogenesis. In target cells, IL-8 induces a series of physiological responses required for migration and phagocytosis, such as increases in intracellular Ca2+, exocytosis (e.g. histamine release), and the respiratory burst.IL-8 can be secreted by any cells with toll-like receptors that are involved in the innate immune response. Usually, it is the macrophages that see an antigen first, and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been reported to be potent inducers of the chemokine receptors CXCR1 and CXCR2. The homodimer is more potent, but methylation of Leu25 can block the activity of homodimers.

Anti-IL-8 Antibody
R1511-15	HUABIO	100ul	EUR 189

Anti-IL-8 antibody
STJ98175	St John's Laboratory	100 µl	EUR 280.8
Description: Mouse monoclonal to IL-8.

Anti-IL-8 antibody
STJ97710	St John's Laboratory	200 µl	EUR 236.4
Description: Mouse monoclonal to IL-8.

Anti-IL-8 antibody
STJ97717	St John's Laboratory	200 µl	EUR 236.4
Description: Mouse monoclonal to IL-8.

Anti-IL-8 antibody
STJ97720	St John's Laboratory	200 µl	EUR 236.4
Description: Mouse monoclonal to IL-8.

Anti-IL-8 Antibody
MBS821263-003mL	MyBiosource	0.03mL	EUR 185

Anti-IL-8 Antibody
MBS821263-01mL	MyBiosource	0.1mL	EUR 255

Anti-IL-8 Antibody
MBS821263-02mL	MyBiosource	0.2mL	EUR 335

Anti-IL-8 Antibody
MBS821263-5x02mL	MyBiosource	5x0.2mL	EUR 1420

Anti-IL-8 antibody
MBS175692-01mg	MyBiosource	0.1mg	EUR 450

Anti-IL-8 antibody
MBS175692-5x01mg	MyBiosource	5x0.1mg	EUR 1870

Anti-IL-8 Antibody
MBS415375-01mL	MyBiosource	0.1mL	EUR 440

Anti-IL-8 Antibody
MBS415375-5x01mL	MyBiosource	5x0.1mL	EUR 1720

human DIAplex Human Inflammation - IL-8, IL-17a,
M880130004	Tecan Benelux	1 unit	EUR 650.27

mAb mouse anti-human IL-8
CT264	U-CyTech	0.5 mg	EUR 312

mouse anti-human IL-8 mAb
E409C16-m100	EnoGene	100μL	EUR 395
Description: Available in various conjugation types.

Mouse anti-Human IL-8 mAb
MBS8576809-005mg	MyBiosource	0.05mg	EUR 325

Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 565

Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 565

Mouse anti-Human IL-8 mAb
MBS8576809-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 565